Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT03064087

Validation of Human Papillomavirus Assays and Collection Devices for Self-samples and Urine Samples

Sponsor: Marc Arbyn

View on ClinicalTrials.gov

Summary

The VALHUDES study is a Diagnostic Test Accuracy study that aims to document the clinical accuracy of hrHPV testing on urine samples, collected under standardised and optimised conditions, and on two types of vaginal self-samples and compare results with those from matching samples taken by a clinician.

Official title: Validation of Human Papillomavirus Assays and Collection Devices for HPV Testing on Self-samples and First-void Urine Samples (VALHUDES)

Key Details

Gender

FEMALE

Age Range

25 Years - 64 Years

Study Type

OBSERVATIONAL

Enrollment

500

Start Date

2017-12-29

Completion Date

2027-11-17

Last Updated

2023-03-29

Healthy Volunteers

Not specified

Interventions

DEVICE

Colli-Pee

First, two first-void urine samples will be collected with the Colli-Pee device (Novosanis NV, Wijnegem, Belgium) at home, the day before a visit to the colposcopy centre at a gynecology clinic.

DEVICE

Multi-Collect Swab

At the colposcopy clinic, one vaginal self-sample will be collected with the Multi-Collect Swab (Abbott GmbH \& Co. KG, Wiesbaden, Germany).

DEVICE

Evalyn Brush

Another vaginal self-sample will be collected also at the colposcopy centre either with the Evalyn Brush (Rovers Medical Devices B.V., Oss, Netherlands)

DEVICE

Qvintip

or with Qvintip (Aprovix AB, Uppsala, Sweden).

DIAGNOSTIC_TEST

Abbott RealTime High Risk HPV

The hrHPV assay used, will be the Abbott PCR (Abbott GmbH \& Co. KG, Wiesbaden, Germany), which detects separately DNA of HPV16 and HPV18, as well as the pool of twelve other hrHPV types (HPV 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68). The accuracy of this PCR assay for the detection of CIN2+ will be determined on all samples: on the first urine sample and on the vaginal and cervical samples. Furthermore, it is possible that in the future other assays will be validated.

Locations (5)

UZ Brussels

Brussels, Brussels Capital, Belgium

UZ Ghent

Ghent, East Flanders, Belgium

Heilig Hart Ziekenhuis Tienen

Tienen, Flemish Brabant, Belgium

UZ Antwerp

Antwerp, Belgium

Centre Hospitalier Universitaire de Liège

Liège, Belgium